Shares of SI-BONE, Inc. (SIBN) surged 5.96% in pre-market trading on Tuesday, following the release of the company's impressive first-quarter 2025 financial results. The medical device maker, known for its minimally invasive surgical devices for the sacroiliac joint, outperformed Wall Street expectations on both earnings and revenue fronts.
SI-BONE reported a quarterly adjusted loss of $0.15 per share, significantly better than the average analyst estimate of a $0.23 loss per share. The company's revenue soared 24.9% year-over-year to $47.29 million, surpassing the Street forecast of $45.17 million. This marks the fourth consecutive quarter that SI-BONE has beaten earnings estimates, demonstrating consistent operational improvement.
The strong quarterly performance has bolstered investor confidence in SI-BONE's growth trajectory. Citizens JMP analyst David Turkaly reiterated a Buy rating on the stock with a price target of $32.00, suggesting substantial upside potential. The current average analyst rating on SI-BONE shares is "buy," with 9 out of 9 analysts recommending either "strong buy" or "buy." Wall Street's median 12-month price target for the stock stands at $24.50, further supporting the bullish sentiment surrounding the company's prospects in the medical equipment and supplies sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.